Enrolling
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
J2A-MC-GZGW - ClinicalTrials.gov - NCT06109311
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor.
Enter your city or zip code to find the nearest site
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 DiabetesWhat the trial is testing?
OrforglipronCould I receive a Placebo?
YesEnrollment Goal
520Trial Dates
Nov 10, 2023 - Jun 2025How long will I be in the trial?
The study will last about 46 weeks and may include up to 20 visits.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have Type 2 Diabetes
Be taking a consistent dose of diabetes drug by injection for at least 3 months
May be taking up to 2 diabetes drugs by mouth for at least 3 months
Have a high blood sugar
Participants Must Not:
Have Type 1 diabetes
Have history of an inflamed pancreas (pancreatitis)
Have history of an inflamed liver (hepatitis)
Have congestive heart failure
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo